Novo Holdings, the controlling shareholder of Novo Nordisk, nearly doubled annual income and investment returns to a record $8.66 billion in 2024, fueled by returns from blockbuster drugs Wegovy and Ozempic. #News #Reuters #Newsfeed #wegovyweightloss #novonordisk #health #pharmaceutical Read the story here: https://reut.rs/3E2yzmh 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest news from around the world: https://www.reuters.com/ Follow Reuters on Facebook: https://www.

Tag-uri: Facebook